Navigating Travel with Novel Oral JAK and BTK Inhibitors: Beyond Biologics

Nagarakanti, Sandhya; Orenstein, Robert

doi:10.30491/ijtmgh.2023.406839.1371

Navigating Travel with Novel Oral JAK and BTK Inhibitors: Beyond Biologics

Document Type : Commentary

Authors

Sandhya Nagarakanti ¹

Robert Orenstein ²

¹ Infectious Diseases, Mayo clinic, Phoenix, Arizona

² Infectious Disease, Mayo Clinic, Phoenix, Arizona

10.30491/ijtmgh.2023.406839.1371

Abstract

The field of immune based therapeutics for treatment of common chronic illnesses has exploded leading to significant improvement in the disease processes but a downstream impact on infections. Janus kinase (JAK) inhibitors and Bruton Tyrosine kinase (BTK) inhibitors are becoming more widely used in treatment of chronic inflammatory diseases and chronic leukemias because of simplicity of oral administration. As such, many patients will have improvement in their underlying illnesses and will have greater flexibility to travel. Thus, it is important for travel medicine practitioners to be aware of these agents, their adverse effects and impact on drug interactions and immunizations.

Keywords

Newer biological therapies

Trip planning

Vaccinations